CMNDNCMHealthcare·Biotechnology#578 in industry

Clearmind Medicine Inc.

-71.0% · 90d

$0.73

-0.08 (-10.09%)

News

(2)

April 2026

Apr 20, 20261 week ago6-KHealthcare

Executive order and bill boost Clearmind's psychedelic drug development

CMNDClearmind Medicine Inc.

# 📰 What This Document Is This filing is an SEC Form 6-K, which is a type of filing used by foreign private issuers (like Clearmind Medicine) to announce material information to U.S. investors. Essentially, this document is a press release designed to inform the public and potential investors about

Read summaryView on SEC EDGAR

March 2026

Mar 30, 20260 months ago6-KHealthcare

Clearmind Medicine Inc. — 6-K Filing

CMNDClearmind Medicine Inc.

# 🧾 What This Document Is This is a **6-K filing**, which is a report public foreign companies (like this Canadian one) file with the SEC to share important news. Think of it as a formal press release channel. This specific one announces a positive update from their ongoing clinical trial. 👉 **Th

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.7M

Open$0.80

Prev Close$0.81

Day Range$0.72 – $0.80

52W Range$0.59 – $52.40

Volume1,980,947

P/E (TTM)—

EPS$-24.12

Dividend Yield—

Beta-1.03

About

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Healthcare · Biotechnology

www.clearmindmedicine.com